COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

7.77%

Decreased from previous period

Growth of 7.77% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

7.03%

Decreased from previous period

Cost growth of 7.03% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

11.04%

Increased from previous period

Growth of 11.04% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

3.03%

Increased from previous period

Margin change of 3.03% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-22.40%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

0.34%

Decreased from previous period

Operating expenses change of 0.34% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

6.04%

Decreased from previous period

Total costs change of 6.04% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-11.11%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-21.27%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

37.84%

Increased from previous period

EBITDA change of 37.84% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

27.89%

Increased from previous period

Margin change of 27.89% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

44.97%

Increased from previous period

Income change of 44.97% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

34.51%

Increased from previous period

Margin change of 34.51% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-15.38%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

39.88%

Increased from previous period

Income change of 39.88% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

29.79%

Increased from previous period

Margin change of 29.79% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

33.49%

Increased from previous period

Tax expense change of 33.49% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

44.92%

Increased from previous period

Income change of 44.92% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

34.47%

Increased from previous period

Margin change of 34.47% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

44.95%

Increased from previous period

EPS change of 44.95% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

44.95%

Increased from previous period

Diluted EPS change of 44.95% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

0.00%

Increased from previous period

Share count change of 0.00% versus stable Healthcare. Walter Schloss would verify approach.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

7.77%

Decreased from previous period

Growth of 7.77% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

7.03%

Decreased from previous period

Cost growth of 7.03% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

11.04%

Increased from previous period

Growth of 11.04% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

3.03%

Increased from previous period

Margin change of 3.03% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Selling & Marketing Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

Other Expenses Growth

-22.40%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

0.34%

Decreased from previous period

Operating expenses change of 0.34% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

6.04%

Decreased from previous period

Total costs change of 6.04% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-11.11%

Decreased from previous period

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-21.27%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

37.84%

Increased from previous period

EBITDA change of 37.84% versus flat Healthcare. Walter Schloss would verify quality.

EBITDA Margin Growth

27.89%

Increased from previous period

Margin change of 27.89% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

44.97%

Increased from previous period

Income change of 44.97% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

34.51%

Increased from previous period

Margin change of 34.51% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-15.38%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

39.88%

Increased from previous period

Income change of 39.88% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

29.79%

Increased from previous period

Margin change of 29.79% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

33.49%

Increased from previous period

Tax expense change of 33.49% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

44.92%

Increased from previous period

Income change of 44.92% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

34.47%

Increased from previous period

Margin change of 34.47% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

44.95%

Increased from previous period

EPS change of 44.95% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

44.95%

Increased from previous period

Diluted EPS change of 44.95% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

0.00%

Increased from previous period

Share count change of 0.00% versus stable Healthcare. Walter Schloss would verify approach.

Share Count Growth (Diluted)

No Data

No Data available this quarter, please select a different quarter.

Select Chart Metric: